Cervical cancer prevention: Who should receive vaccination? Commentary

Nature Clinical Practice Oncology

Volumn 5, Issue 1, 2008, Pages 12-13

  Meijer, Chris J L M ^a   Berkhof, Johannes ^a   Heideman, Daniëlle A M ^a   Snijders, Peter J F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

ANTIBODY TITER; CANCER GRADING; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOLOGY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INJECTION SITE PAIN; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT;

EID: 41949136084     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0976     Document Type: Short Survey

References (4)

1. Harper DM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367: 1247-1255
2. Cuzick J et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-1101
3. Ronco G et al. (2006) Human papillomavirus testing and liquid-based cytology: Results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 98: 765-774
4. Bulkmans NW et al: High-risk human papillomavirus testing detects cervical intraepithelial neoplasia grade 3 and cancer earlier than cytology in cervical screening permitting extension of the screening interval: Five-year follow-up results of the randomised controlled. POBASCAM trial. Lancet, in press.